On Tuesday, Liquidia hit a key technical benchmark, with its Relative Strength (RS) Rating entering into the 80-plus percentile with an improvement to 82, an increase from 77 the day before.
Hone Your Stock-Picking Skills By Focusing On These Factors
IBD's proprietary rating tracks share price performance with a 1 (worst) to 99 (best) score. The score shows how a stock's price behavior over the last 52 weeks holds up against all the other stocks in our database.
Over 100 years of market history reveals that the best stocks typically have an RS Rating north of 80 as they begin their biggest price moves.
While Liquidia is not near a proper entry right now, see if it manages to form and break out from a proper consolidation.
Liquidia posted 0% earnings growth in its most recent report, while sales growth came in at 5%. The company is expected to report its latest performance numbers on or around Aug. 7.
Liquidia earns the No. 231 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, TG Therapeutics and Inhibrx Biosciences are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Which Stocks Are Showing Improved Price Performance?
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
